Compare DCO & SUPN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DCO | SUPN |
|---|---|---|
| Founded | 1849 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Military/Government/Technical | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.8B |
| IPO Year | 1995 | 2010 |
| Metric | DCO | SUPN |
|---|---|---|
| Price | $182.16 | $45.27 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 5 | 5 |
| Target Price | ★ $153.60 | $61.60 |
| AVG Volume (30 Days) | 203.6K | ★ 935.2K |
| Earning Date | 05-12-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.95 | N/A |
| Revenue | ★ $824,730,000.00 | $392,755,000.00 |
| Revenue This Year | $7.40 | $22.70 |
| Revenue Next Year | $8.59 | $19.14 |
| P/E Ratio | $93.01 | ★ N/A |
| Revenue Growth | ★ 4.85 | N/A |
| 52 Week Low | $84.76 | $42.45 |
| 52 Week High | $210.39 | $59.68 |
| Indicator | DCO | SUPN |
|---|---|---|
| Relative Strength Index (RSI) | 45.10 | 42.17 |
| Support Level | $165.13 | $44.07 |
| Resistance Level | $209.83 | $46.79 |
| Average True Range (ATR) | 6.73 | 1.37 |
| MACD | -2.96 | -0.28 |
| Stochastic Oscillator | 8.44 | 16.53 |
Ducommun Inc provides engineering & manufacturing services for high-performance products & high-cost-of failure applications used in the aerospace and defense, industrial, medical & other industries. The company's reportable segments are Structural Systems & Electronic Systems. Structural Systems designs, engineers, and manufactures various sizes of complex contoured aerostructure components and assemblies, and supplies composite and metal-bonded structures and assemblies. Electronic Systems designs, engineers and manufactures high-reliability electronic and electromechanical products used in technology-driven markets, including A&D and Industrial end-use markets. It generates a maximum of its revenue from the Electronic Systems.
Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.